If you have followed the news on “stent war legal cases” then you know what I am talking about as J and cashed in very big over the last year or so with the Boston Scientific case for one example so we could be assured of legally patented stents and now they are not going to make them anymore?
Johnson and Johnson Revenue Increased – Helped Along with “Stent War” Settlements
Go figure, I know just another business decision:) There were a few smaller cases though where J and J had to pay but the Boston Scientific ruling overshadowed those cases by a mile where J and J benefited. The company will stop manufacturing of the CYPHER® and CYPHER SELECT® Plus Stents at the end of the year.
Where’s Some of the Focus for Johnson and Johnson Revenue Cycles – “Legally Patented Stent Wars”?
The legal battles over the last few years were expensive but I think this was one area that escaped any major recall efforts.
Will the “Stent Wars” Ever End – We Want to Be Able to Afford them Boston Scientific Files Cross Appeal
Future Plans and Explanation:
“A short while ago, we announced to employees of our Cordis Franchise that we will stop manufacturing CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary Stents by the end of 2011 and we will not pursue the development of the NEVO™ Sirolimus-Eluting Coronary Stent in order to better focus on those areas of the Cardiovascular market with the most significant medical needs and the greatest opportunities for growth.
As many of you know, Cordis introduced the world’s first bare-metal coronary stent in 1994, as well as the world’s first drug-eluting stent (DES), the CYPHER® Sirolimus-eluting Coronary Stent, in 2002. Since then, the CYPHER® Stent has been chosen by cardiologists worldwide to treat more than three million patients with coronary artery disease. Coronary stenting truly ranks as one of the great breakthroughs in the history of medical technology. 
A short while ago, we announced to employees of our Cordis Franchise that we will stop manufacturing CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary Stents by the end of 2011 and we will not pursue the development of the NEVO™ Sirolimus-Eluting Coronary Stent in order to better focus on those areas of the Cardiovascular market with the most significant medical needs and the greatest opportunities for growth.
As many of you know, Cordis introduced the world’s first bare-metal coronary stent in 1994, as well as the world’s first drug-eluting stent (DES), the CYPHER® Sirolimus-eluting Coronary Stent, in 2002. Since then, the CYPHER® Stent has been chosen by cardiologists worldwide to treat more than three million patients with coronary artery disease. Coronary stenting truly ranks as one of the great breakthroughs in the history of medical technology.”
In addition it was noted with current re-structuring that 900 to 1000 positions will be eliminated as well so now I guess we finally have an end to the ever so expensive stent wars and the cases must be wrapping up and the profit levels might be dipping. J and J has a whole new group to work with now as they acquired the Synthes Corporation so I think there’s a lot of work involved there coming up as well. There’s a big privately owned company, Cook Medical who I have interviewed several times on this blog who also produces a line of stents so they may stand to pickup some business as well. BD
Johnson & Johnson is to close its Cashel manufacturing plant with the loss of 133 jobs, it was confirmed this afternoon.
The decision comes as Cordis Corporation, a Johnson & Johnson company, said it would stop manufacturing its Cypher drug-coated heart stents by the end of the year and end development of a new model.
Cashel plant closure sees 133 jobs lost - The Irish Times - Wed, Jun 15, 2011
Tidak ada komentar:
Posting Komentar